<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02519920</url>
  </required_header>
  <id_info>
    <org_study_id>2015SDU-QILU-G08</org_study_id>
    <nct_id>NCT02519920</nct_id>
  </id_info>
  <brief_title>Lower Fluorescein Sodium Dose on Confocal Laser Endoscopy Image Quality and Yellow Discoloration of the Skin</brief_title>
  <official_title>Lower Fluorescein Sodium Dose on Confocal Laser Endoscopy Image Quality and Yellow Discoloration of the Skin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shandong University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shandong University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study was to test an appropriate dose of fluorescein sodium which can provide high image
      quality to ensure endoscopy examination and have no yellow dye in the skin by a randomized
      blinded controlled trial.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Fluorescein sodium is one of the commonly used staining agents in confocal laser endoscopy, a
      device for in vivo real-time histological observation of the gastrointestinal mucosa. The
      conventional intravenous dosage of fluorescein sodium is in the range of 5ml to 10ml of 10%
      fluorescein. Image quality can be guaranteed with this range of fluorescein sodium, but
      yellow discoloration of the skin seriously influences daily life. This study was to test
      whether a lower dose of fluorescein sodium, which has minimal discoloration of skin, can
      provide satisfied image quality by a randomized blinded controlled trial.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2015</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Different ratios of high resolution CLE images among four different fluorescein sodium dose groups(0.01ml/kg,0.02ml/kg,0.05ml/kg,0.1ml/kg)</measure>
    <time_frame>six months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Different degrees of skin yellow dye of patients in four different fluorescein sodium dose groups(0.01ml/kg,0.02ml/kg,0.05ml/kg,0.1ml/kg)</measure>
    <time_frame>six months</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">63</enrollment>
  <condition>Image Quality</condition>
  <condition>Skin Discoloration</condition>
  <arm_group>
    <arm_group_label>group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This group patients were given dosages of fluorescein sodium 0.01ml/kg intravenous administration.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This group patients were given dosages of fluorescein sodium 0.02ml/kg intravenous administration.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This group patients were given dosages of fluorescein sodium 0.05ml/kg intravenous administration.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group 4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group patients were given dosages of fluorescein sodium 0.1ml/kg intravenous administration.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluorescein sodium 0.01ml/kg</intervention_name>
    <description>fluorescein Sodium Dose of 0.01ml/kg on confocal laser endoscopy image quality and yellow discoloration of the skin</description>
    <arm_group_label>group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluorescein sodium 0.02ml/kg</intervention_name>
    <description>fluorescein Sodium Dose of 0.02ml/kg on confocal laser endoscopy image quality and yellow discoloration of the skin</description>
    <arm_group_label>group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluorescein sodium 0.05ml/kg</intervention_name>
    <description>fluorescein Sodium Dose of 0.05ml/kg on confocal laser endoscopy image quality and yellow discoloration of the skin</description>
    <arm_group_label>group 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluorescein sodium 0.1ml/kg</intervention_name>
    <description>fluorescein Sodium Dose of 0.1ml/kg on confocal laser endoscopy image quality and yellow discoloration of the skin</description>
    <arm_group_label>group 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Only those with normal mucosa and minor gastritis from 18 were included.

          -  patients with aged 18 years to 80 years

          -  patients with normal mucosa and minor gastritis

          -  willing to provide informed consent

        Exclusion Criteria:

          -  serious coagulopathy dysfunction, severe cardiopulmonary disease, bronchial asthma,
             liver and kidney dysfunction, allergy to fluorescein, pregnancy women or breast
             feeding.

          -  patients with peptic ulcer, gastric cancer, remnant stomach, acute serious gastritis
             were also excluded.

          -  unwilling to provide informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yanqing Li, PhD.MD</last_name>
    <role>Study Director</role>
    <affiliation>Department of Gastroenterology,Qilu Hospital,Shandong University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yanqing Li, PhD.MD</last_name>
    <phone>18678827666</phone>
    <phone_ext>82169508</phone_ext>
    <email>qiluliyanqing@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Gastroenterology, Qilu Hospital, Shandong University</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250012</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yanqing Li, MD, PhD</last_name>
      <phone>86-531-82169236</phone>
      <phone_ext>82169508</phone_ext>
      <email>liyanqing@sdu.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 3, 2015</study_first_submitted>
  <study_first_submitted_qc>August 10, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 11, 2015</study_first_posted>
  <last_update_submitted>October 19, 2015</last_update_submitted>
  <last_update_submitted_qc>October 19, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 20, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shandong University</investigator_affiliation>
    <investigator_full_name>Yanqing Li</investigator_full_name>
    <investigator_title>Vice president of Qilu Hospital</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

